BNP Paribas Financial Markets Sells 67,370 Shares of Inspire Medical Systems, Inc. $INSP

BNP Paribas Financial Markets decreased its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 12.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 454,810 shares of the company’s stock after selling 67,370 shares during the period. BNP Paribas Financial Markets’ holdings in Inspire Medical Systems were worth $41,947,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Regal Partners Ltd bought a new position in Inspire Medical Systems during the third quarter valued at approximately $7,547,000. Illinois Municipal Retirement Fund lifted its position in Inspire Medical Systems by 262.0% during the third quarter. Illinois Municipal Retirement Fund now owns 25,424 shares of the company’s stock valued at $1,886,000 after purchasing an additional 18,400 shares during the period. State of New Jersey Common Pension Fund D lifted its position in Inspire Medical Systems by 79.9% during the third quarter. State of New Jersey Common Pension Fund D now owns 23,216 shares of the company’s stock valued at $1,723,000 after purchasing an additional 10,311 shares during the period. Rheos Capital Works Inc. lifted its position in Inspire Medical Systems by 124.0% during the fourth quarter. Rheos Capital Works Inc. now owns 117,400 shares of the company’s stock valued at $10,828,000 after purchasing an additional 65,000 shares during the period. Finally, Aberdeen Group plc lifted its position in Inspire Medical Systems by 16.3% during the fourth quarter. Aberdeen Group plc now owns 460,901 shares of the company’s stock valued at $42,509,000 after purchasing an additional 64,561 shares during the period. Institutional investors own 94.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on INSP shares. Bank of America downgraded shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective on the stock. in a research report on Friday, May 22nd. Wolfe Research cut shares of Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a research note on Friday, February 13th. Weiss Ratings downgraded shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Morgan Stanley set a $60.00 price objective on shares of Inspire Medical Systems in a research report on Wednesday, February 18th. Finally, Wells Fargo & Company reduced their price objective on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 5th. Four analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $81.84.

Inspire Medical Systems Price Performance

Shares of NYSE INSP opened at $40.42 on Thursday. The firm has a fifty day moving average price of $49.34 and a 200-day moving average price of $73.82. The stock has a market cap of $1.16 billion, a PE ratio of 9.00, a price-to-earnings-growth ratio of 4.19 and a beta of 0.73. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, research analysts expect that Inspire Medical Systems, Inc. will post 0.91 EPS for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.